Pre-Recorded

Plenary Presentation

ILD and Friends

Recent advances in therapeutic options, including the advent of antifibrotic therapies beyond IPF and use of immunosuppressive agents in other ILDs, have led to more purposeful management among these patients. However, treatment benefits seen in pharmaceutical trials are not always applicable to the general ILD population where comorbid conditions significantly affect morbidity and mortality. Strategies for the management of comorbidities associated with ILD are potentially beneficial but the evidence is controversial. This session will involve a diverse group of expert providers discussing current evidence in managing comorbidities such as gastroesophageal reflux, pulmonary hypertension, sleep disordered breathing, and sarcopenia.

Integrate a holistic and interdisciplinary approach to ILD patient care.

Identify ILD patients who would benefit from pharmacological therapy for their comorbidities.